25 XP   0   0   10

Effector Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Effector together

PenkeI guess you are interested in Effector Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Effector Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Effector Therapeutics Inc

I send you an email if I find something interesting about Effector Therapeutics Inc.

Quick analysis of Effector (30 sec.)










What can you expect buying and holding a share of Effector? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
7.1%

What is your share worth?

Current worth
$-1.70
Expected worth in 1 year
$-4.53
How sure are you?
35.7%

+ What do you gain per year?

Total Gains per Share
$-2.84
Return On Investment
-159.3%

For what price can you sell your share?

Current Price per Share
$1.78
Expected price per share
$0 - $8.625
How sure are you?
50%

1. Valuation of Effector (5 min.)




Live pricePrice per Share (EOD)

$1.78

Intrinsic Value Per Share

$-31.94 - $-35.02

Total Value Per Share

$-33.63 - $-36.72

2. Growth of Effector (5 min.)




Is Effector growing?

Current yearPrevious yearGrowGrow %
How rich?-$5.7m$15m-$18m-602.7%

How much money is Effector making?

Current yearPrevious yearGrowGrow %
Making money-$8.9m-$5.6m-$3.2m-36.7%
Net Profit Margin0.0%-618.6%--

How much money comes from the company's main activities?

3. Financial Health of Effector (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#938 / 1016

Most Revenue
#1000 / 1016

Most Profit
#531 / 1016

Most Efficient
#446 / 1016

What can you expect buying and holding a share of Effector? (5 min.)

Welcome investor! Effector's management wants to use your money to grow the business. In return you get a share of Effector.

What can you expect buying and holding a share of Effector?

First you should know what it really means to hold a share of Effector. And how you can make/lose money.

Speculation

The Price per Share of Effector is $1.78. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Effector.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Effector, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.70. Based on the TTM, the Book Value Change Per Share is $-0.71 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.98 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Effector.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2.67-150.1%-2.62-147.2%-1.66-93.2%-1.06-59.5%-1.06-59.5%
Usd Book Value Change Per Share-0.54-30.1%-0.71-39.8%-0.98-55.0%-0.12-6.8%-0.12-6.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.2%0.000.0%0.000.0%
Usd Total Gains Per Share-0.54-30.1%-0.71-39.8%-0.98-54.9%-0.12-6.8%-0.12-6.8%
Usd Price Per Share0.47-0.56-1.61-3.62-3.62-
Price to Earnings Ratio-0.04--0.06-0.21-12.24-12.24-
Price-to-Total Gains Ratio-0.87--0.24-0.11-0.08-0.08-
Price to Book Ratio-0.28-0.01-0.33--0.23--0.23-
Price-to-Total Gains Ratio-0.87--0.24-0.11-0.08-0.08-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.78
Number of shares561
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.71-0.12
Usd Total Gains Per Share-0.71-0.12
Gains per Quarter (561 shares)-397.81-67.53
Gains per Year (561 shares)-1,591.23-270.13
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1591-16012-272-280
20-3182-31923-544-550
30-4774-47835-816-820
40-6365-63747-1087-1090
50-7956-79659-1359-1360
60-9547-955610-1631-1630
70-11139-1114712-1903-1900
80-12730-1273814-2175-2170
90-14321-1432916-2447-2440
100-15912-1592017-2719-2710

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%4.08.00.033.3%4.010.00.028.6%4.010.00.028.6%4.010.00.028.6%
Book Value Change Per Share1.03.00.025.0%5.07.00.041.7%5.08.01.035.7%5.08.01.035.7%5.08.01.035.7%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.013.07.1%1.00.013.07.1%1.00.013.07.1%
Total Gains per Share1.03.00.025.0%5.07.00.041.7%5.08.01.035.7%5.08.01.035.7%5.08.01.035.7%

Fundamentals of Effector

About Effector Therapeutics Inc

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Fundamental data was last updated by Penke on 2024-03-31 10:39:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Effector Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Effector earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Effector to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Effector Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-618.6%+618.6%
TTM-5Y-95.3%+95.3%
5Y-95.3%10Y-95.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--197.2%+197.2%
TTM--210.4%+210.4%
YOY-618.6%-279.3%-339.3%
5Y-95.3%-436.8%+341.5%
10Y-95.3%-599.3%+504.0%
1.1.2. Return on Assets

Shows how efficient Effector is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Effector to the Biotechnology industry mean.
  • -44.4% Return on Assets means that Effector generated $-0.44 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Effector Therapeutics Inc:

  • The MRQ is -44.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -40.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-44.4%TTM-40.6%-3.8%
TTM-40.6%YOY-16.9%-23.7%
TTM-40.6%5Y-16.1%-24.5%
5Y-16.1%10Y-16.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-44.4%-13.6%-30.8%
TTM-40.6%-12.9%-27.7%
YOY-16.9%-11.9%-5.0%
5Y-16.1%-14.2%-1.9%
10Y-16.1%-16.2%+0.1%
1.1.3. Return on Equity

Shows how efficient Effector is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Effector to the Biotechnology industry mean.
  • 0.0% Return on Equity means Effector generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Effector Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-81.2%+81.2%
TTM-81.2%YOY-85.9%+4.7%
TTM-81.2%5Y-40.1%-41.1%
5Y-40.1%10Y-40.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--17.0%+17.0%
TTM-81.2%-16.1%-65.1%
YOY-85.9%-15.4%-70.5%
5Y-40.1%-20.0%-20.1%
10Y-40.1%-21.1%-19.0%

1.2. Operating Efficiency of Effector Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Effector is operating .

  • Measures how much profit Effector makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Effector to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Effector Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-590.8%+590.8%
TTM-5Y-1,242.3%+1,242.3%
5Y-1,242.3%10Y-1,242.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM--224.4%+224.4%
YOY-590.8%-288.4%-302.4%
5Y-1,242.3%-475.2%-767.1%
10Y-1,242.3%-624.7%-617.6%
1.2.2. Operating Ratio

Measures how efficient Effector is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Effector Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY5.913-5.913
TTM-5Y14.370-14.370
5Y14.37010Y14.3700.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.997-2.997
TTM-3.247-3.247
YOY5.9133.766+2.147
5Y14.3705.675+8.695
10Y14.3707.857+6.513

1.3. Liquidity of Effector Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Effector is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.77 means the company has $0.77 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Effector Therapeutics Inc:

  • The MRQ is 0.769. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.866. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.769TTM0.866-0.097
TTM0.866YOY5.678-4.812
TTM0.8665Y3.877-3.011
5Y3.87710Y3.8770.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7693.930-3.161
TTM0.8664.251-3.385
YOY5.6785.436+0.242
5Y3.8776.045-2.168
10Y3.8776.363-2.486
1.3.2. Quick Ratio

Measures if Effector is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Effector to the Biotechnology industry mean.
  • A Quick Ratio of 0.85 means the company can pay off $0.85 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Effector Therapeutics Inc:

  • The MRQ is 0.850. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.165. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ0.850TTM1.165-0.316
TTM1.165YOY8.695-7.530
TTM1.1655Y4.507-3.342
5Y4.50710Y4.5070.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8503.629-2.779
TTM1.1654.065-2.900
YOY8.6955.397+3.298
5Y4.5075.993-1.486
10Y4.5076.277-1.770

1.4. Solvency of Effector Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Effector assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Effector to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.28 means that Effector assets are financed with 128.2% credit (debt) and the remaining percentage (100% - 128.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Effector Therapeutics Inc:

  • The MRQ is 1.282. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.151. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.282TTM1.151+0.131
TTM1.151YOY0.647+0.503
TTM1.1515Y2.076-0.925
5Y2.07610Y2.0760.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2820.332+0.950
TTM1.1510.334+0.817
YOY0.6470.268+0.379
5Y2.0760.366+1.710
10Y2.0760.390+1.686
1.4.2. Debt to Equity Ratio

Measures if Effector is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Effector to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Effector Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.361-2.361
TTM2.361YOY2.703-0.342
TTM2.3615Y1.603+0.757
5Y1.60310Y1.6030.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.381-0.381
TTM2.3610.390+1.971
YOY2.7030.334+2.369
5Y1.6030.434+1.169
10Y1.6030.466+1.137

2. Market Valuation of Effector Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Effector generates.

  • Above 15 is considered overpriced but always compare Effector to the Biotechnology industry mean.
  • A PE ratio of -0.04 means the investor is paying $-0.04 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Effector Therapeutics Inc:

  • The EOD is -0.167. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.044. Based on the earnings, the company is expensive. -2
  • The TTM is -0.055. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.167MRQ-0.044-0.123
MRQ-0.044TTM-0.055+0.011
TTM-0.055YOY0.213-0.268
TTM-0.0555Y12.236-12.291
5Y12.23610Y12.2360.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.167-2.315+2.148
MRQ-0.044-2.560+2.516
TTM-0.055-2.664+2.609
YOY0.213-4.122+4.335
5Y12.236-6.258+18.494
10Y12.236-6.108+18.344
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Effector Therapeutics Inc:

  • The EOD is -0.271. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.071. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.065. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.271MRQ-0.071-0.199
MRQ-0.071TTM-0.065-0.006
TTM-0.065YOY-0.226+0.161
TTM-0.0655Y-0.500+0.436
5Y-0.50010Y-0.5000.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.271-3.067+2.796
MRQ-0.071-3.251+3.180
TTM-0.065-3.545+3.480
YOY-0.226-5.595+5.369
5Y-0.500-8.315+7.815
10Y-0.500-8.708+8.208
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Effector is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.28 means the investor is paying $-0.28 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Effector Therapeutics Inc:

  • The EOD is -1.049. Based on the equity, the company is expensive. -2
  • The MRQ is -0.276. Based on the equity, the company is expensive. -2
  • The TTM is 0.015. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-1.049MRQ-0.276-0.774
MRQ-0.276TTM0.015-0.290
TTM0.015YOY0.334-0.319
TTM0.0155Y-0.233+0.248
5Y-0.23310Y-0.2330.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.0491.905-2.954
MRQ-0.2762.111-2.387
TTM0.0152.095-2.080
YOY0.3342.836-2.502
5Y-0.2333.443-3.676
10Y-0.2333.794-4.027
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Effector Therapeutics Inc.

3.1. Institutions holding Effector Therapeutics Inc

Institutions are holding 18.023% of the shares of Effector Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30The Carlyle Group Inc5.64550.1244482211400
2023-09-30Sectoral Asset Management Inc2.78950.2783238264400
2023-09-30Parallel Advisors, LLC1.98270.0338169355900
2023-09-30Blackstone Inc1.5320.0033130858700
2023-09-30OUP Management Co., LLC1.20081.3838102569700
2023-09-30Vanguard Group Inc0.4730404026-1893-0.4663
2023-09-30Geode Capital Management, LLC0.30880263758158776151.2412
2023-09-30Sonora Investment Management Group, LLC0.14630.00641250001250000
2023-09-30Northern Trust Corp0.04310368141082141.6304
2023-09-30Wescott Financial Advisory Group, LLC0.03580.00343055600
2023-09-30Stifel Financial Corp0.0265022660226600
2023-09-30State Street Corporation0.023502008500
2023-09-30Callan Capital, LLC0.02340.00132000000
2023-09-30Morgan Stanley - Brokerage Accounts0.0233019920192010.6667
2023-09-30Vontobel Holding Ltd.0.01760.00011500000
2023-09-30Tower Research Capital LLC0.01440.000212334194918.7675
2023-09-30UBS Group AG0.01160987498740
2023-09-30BlackRock Inc0.0006055400
2023-09-30Royal Bank of Canada0.00050406112.7848
2023-09-30Wells Fargo & Co0.00030297218275.9494
Total 14.29921.83512213885+329336+2.7%

3.2. Funds holding Effector Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.13540.00091156371059961099.4295
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.10870.000992873851441101.6173
2024-02-29Vanguard Total Stock Mkt Idx Inv1.54540.00015280100
2023-12-31Northern Trust Extended Eq Market Idx0.0420.00033583918002100.925
2023-12-31NT Ext Equity Mkt Idx Fd - L0.0420.00033583918002100.925
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.60980.0003208341024196.6771
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.011209544-290489-96.819
2024-01-31Fidelity Extended Market Index0.24990.00038538-1-0.0117
2023-12-31SSgA U.S. Extended Market Index Class I0.00490.0001420000
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.00440.0009373934281102.2508
2024-01-31Fidelity Series Total Market Index0.09610.0001328500
2024-01-31Fidelity Total Market Index0.075702586-1-0.0387
2024-01-31Fidelity Nasdaq Composite Index0.04850.0001165800
2023-12-31SSgA U.S. Total Market Index Strategy0.001401211-28-2.2599
2023-09-30BlackRock Extended Mkt Composite0.0006055400
2023-12-31BlackRock Extended Equity Market K0.00060483-1-0.2066
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.0112038200
2024-01-31Spartan Total Market Index Pool E0.0054018300
2024-02-29State St US Extended Mkt Indx NL Cl C0.00490.000116800
2023-12-31Extended Equity Market Fund M0.000106035.2632
Total 2.99820.0044390414-49704-12.7%

3.3. Insider Transactions

Insiders are holding 3.706% of the shares of Effector Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-11-27Sr One Capital Management, LlcSELL2436615.25

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Effector Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.535-0.709+32%-0.980+83%-0.121-77%-0.121-77%
Book Value Per Share---1.696-0.878-48%4.413-138%-1.087-36%-1.087-36%
Current Ratio--0.7690.866-11%5.678-86%3.877-80%3.877-80%
Debt To Asset Ratio--1.2821.151+11%0.647+98%2.076-38%2.076-38%
Debt To Equity Ratio---2.361-100%2.703-100%1.603-100%1.603-100%
Dividend Per Share----0%0.003-100%0.001-100%0.001-100%
Eps---2.672-2.620-2%-1.658-38%-1.060-60%-1.060-60%
Free Cash Flow Per Share---1.645-2.169+32%-1.909+16%-2.001+22%-2.001+22%
Free Cash Flow To Equity Per Share--0.143-0.616+530%-1.707+1293%-0.311+317%-0.311+317%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---35.020--------
Intrinsic Value_10Y_min---31.937--------
Intrinsic Value_1Y_max---7.249--------
Intrinsic Value_1Y_min---7.122--------
Intrinsic Value_3Y_max---18.930--------
Intrinsic Value_3Y_min---18.130--------
Intrinsic Value_5Y_max---27.175--------
Intrinsic Value_5Y_min---25.469--------
Market Cap6081601.400+74%1596932.8621922025.207-17%5491976.478-71%12360586.396-87%12360586.396-87%
Net Profit Margin----0%-6.1860%-0.9530%-0.9530%
Operating Margin----0%-5.9080%-12.4230%-12.4230%
Operating Ratio----0%5.913-100%14.370-100%14.370-100%
Pb Ratio-1.049-281%-0.2760.015-1975%0.334-183%-0.233-15%-0.233-15%
Pe Ratio-0.167-281%-0.044-0.055+26%0.213-121%12.236-100%12.236-100%
Price Per Share1.780+74%0.4670.563-17%1.607-71%3.618-87%3.618-87%
Price To Free Cash Flow Ratio-0.271-281%-0.071-0.065-9%-0.226+218%-0.500+605%-0.500+605%
Price To Total Gains Ratio-3.325-281%-0.873-0.235-73%0.106-922%0.081-1178%0.081-1178%
Quick Ratio--0.8501.165-27%8.695-90%4.507-81%4.507-81%
Return On Assets---0.444-0.406-9%-0.169-62%-0.161-64%-0.161-64%
Return On Equity----0.8120%-0.8590%-0.4010%-0.4010%
Total Gains Per Share---0.535-0.709+32%-0.977+82%-0.120-78%-0.120-78%
Usd Book Value---5795000.000-2999750.000-48%15078250.000-138%-3713561.571-36%-3713561.571-36%
Usd Book Value Change Per Share---0.535-0.709+32%-0.980+83%-0.121-77%-0.121-77%
Usd Book Value Per Share---1.696-0.878-48%4.413-138%-1.087-36%-1.087-36%
Usd Dividend Per Share----0%0.003-100%0.001-100%0.001-100%
Usd Eps---2.672-2.620-2%-1.658-38%-1.060-60%-1.060-60%
Usd Free Cash Flow---5620000.000-7411750.000+32%-6522750.000+16%-6836428.571+22%-6836428.571+22%
Usd Free Cash Flow Per Share---1.645-2.169+32%-1.909+16%-2.001+22%-2.001+22%
Usd Free Cash Flow To Equity Per Share--0.143-0.616+530%-1.707+1293%-0.311+317%-0.311+317%
Usd Market Cap6081601.400+74%1596932.8621922025.207-17%5491976.478-71%12360586.396-87%12360586.396-87%
Usd Price Per Share1.780+74%0.4670.563-17%1.607-71%3.618-87%3.618-87%
Usd Profit---9129000.000-8952500.000-2%-5666250.000-38%-3620214.286-60%-3620214.286-60%
Usd Revenue----0%385500.000-100%286785.714-100%286785.714-100%
Usd Total Gains Per Share---0.535-0.709+32%-0.977+82%-0.120-78%-0.120-78%
 EOD+6 -2MRQTTM+13 -15YOY+14 -185Y+11 -2110Y+11 -21

4.2. Fundamental Score

Let's check the fundamental score of Effector Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.167
Price to Book Ratio (EOD)Between0-1-1.049
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.850
Current Ratio (MRQ)Greater than10.769
Debt to Asset Ratio (MRQ)Less than11.282
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.444
Total1/10 (10.0%)

4.3. Technical Score

Let's check the technical score of Effector Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5026.666
Ma 20Greater thanMa 507.576
Ma 50Greater thanMa 10010.440
Ma 100Greater thanMa 20011.033
OpenGreater thanClose1.910
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets20,544
Total Liabilities26,339
Total Stockholder Equity-5,795
 As reported
Total Liabilities 26,339
Total Stockholder Equity+ -5,795
Total Assets = 20,544

Assets

Total Assets20,544
Total Current Assets19,838
Long-term Assets706
Total Current Assets
Cash And Cash Equivalents 14,875
Short-term Investments 3,495
Net Receivables 52
Other Current Assets 1,416
Total Current Assets  (as reported)19,838
Total Current Assets  (calculated)19,838
+/-0
Long-term Assets
Property Plant Equipment 193
Long-term Assets Other 513
Long-term Assets  (as reported)706
Long-term Assets  (calculated)706
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities25,796
Long-term Liabilities543
Total Stockholder Equity-5,795
Total Current Liabilities
Short-term Debt 19,445
Short Long Term Debt 20,485
Accounts payable 2,330
Other Current Liabilities 4,021
Total Current Liabilities  (as reported)25,796
Total Current Liabilities  (calculated)46,281
+/- 20,485
Long-term Liabilities
Capital Lease Obligations 60
Long-term Liabilities  (as reported)543
Long-term Liabilities  (calculated)60
+/- 483
Total Stockholder Equity
Retained Earnings -179,377
Other Stockholders Equity 173,582
Total Stockholder Equity (as reported)-5,795
Total Stockholder Equity (calculated)-5,795
+/-0
Other
Cash and Short Term Investments 18,370
Common Stock Shares Outstanding 2,670
Liabilities and Stockholders Equity 20,544
Net Debt 4,570
Net Invested Capital 14,690
Net Working Capital -5,958
Property Plant and Equipment Gross 517
Short Long Term Debt Total 19,445



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-03-31
> Total Assets 
0
0
16,704
176,817
14,281
59,936
54,056
49,495
43,471
36,651
29,077
21,928
26,889
20,161
20,544
20,54420,16126,88921,92829,07736,65143,47149,49554,05659,93614,281176,81716,70400
   > Total Current Assets 
0
16,578
16,578
1,813
12,034
58,941
52,896
48,339
42,283
35,521
28,014
20,894
25,975
19,282
19,838
19,83819,28225,97520,89428,01435,52142,28348,33952,89658,94112,0341,81316,57816,5780
       Cash And Cash Equivalents 
0
0
15,216
1,468
10,880
54,768
49,702
17,664
16,353
11,903
8,708
10,310
14,714
5,386
14,875
14,8755,38614,71410,3108,70811,90316,35317,66449,70254,76810,8801,46815,21600
       Short-term Investments 
0
0
0
0
0
0
0
28,042
24,685
21,053
17,602
8,697
10,305
12,393
3,495
3,49512,39310,3058,69717,60221,05324,68528,0420000000
       Net Receivables 
0
0
0
1
500
1,100
100
0
500
400
27
42
72
23
52
522372422740050001001,1005001000
       Other Current Assets 
0
0
1,362
345
1,154
4,173
3,194
2,633
1,245
2,565
1,704
1,887
956
1,503
1,416
1,4161,5039561,8871,7042,5651,2452,6333,1944,1731,1543451,36200
   > Long-term Assets 
0
0
126
175,004
2,247
995
1,160
1,156
1,188
1,130
1,063
1,034
914
879
706
7068799141,0341,0631,1301,1881,1561,1609952,247175,00412600
       Property Plant Equipment 
0
126
126
97
68
45
257
302
381
371
352
311
299
312
193
1933122993113523713813022574568971261260
       Other Assets 
0
0
178
56
2,179
950
903
854
807
759
711
0
615
0
0
0061507117598078549039502,1795617800
> Total Liabilities 
0
0
148,949
10,481
158,291
67,605
36,772
24,261
23,848
25,091
25,181
26,741
24,314
24,127
26,339
26,33924,12724,31426,74125,18125,09123,84824,26136,77267,605158,29110,481148,94900
   > Total Current Liabilities 
0
8,779
8,779
241
5,399
46,347
3,978
2,630
23,585
24,968
25,075
26,652
23,759
23,588
25,796
25,79623,58823,75926,65225,07524,96823,5852,6303,97846,3475,3992418,7798,7790
       Short-term Debt 
0
0
6,015
0
55
28
44
46
20,059
20,139
20,221
20,303
20,385
20,470
19,445
19,44520,47020,38520,30320,22120,13920,0594644285506,01500
       Short Long Term Debt 
0
0
5,907
0
0
0
0
0
20,011
20,085
20,161
20,237
20,316
20,399
20,485
20,48520,39920,31620,23720,16120,08520,011000005,90700
       Accounts payable 
0
347
347
241
1,907
321
516
294
1,204
1,214
1,486
3,794
1,451
1,136
2,330
2,3301,1361,4513,7941,4861,2141,2042945163211,9072413473470
       Other Current Liabilities 
0
784
433
1,104
780
43,250
3,418
2,290
2,322
3,615
3,368
2,555
1,923
1,982
4,021
4,0211,9821,9232,5553,3683,6152,3222,2903,41843,2507801,1044337840
   > Long-term Liabilities 
0
0
140,170
10,240
152,892
21,258
32,794
21,631
263
123
106
89
555
539
543
5435395558910612326321,63132,79421,258152,89210,240140,17000
       Warrants
0
0
0
161,336
156,631
0
0
0
0
0
0
0
0
0
0
0000000000156,631161,336000
       Other Liabilities 
0
0
0
0
0
1,495
12,808
1,606
169
46
46
0
530
0
0
00530046461691,60612,8081,49500000
> Total Stockholder Equity
0
0
-132,245
166,336
-144,010
-7,669
17,284
25,234
19,623
11,560
3,896
-4,813
2,575
-3,966
-5,795
-5,795-3,9662,575-4,8133,89611,56019,62325,23417,284-7,669-144,010166,336-132,24500
   Common Stock
0
1
0
1
2
4
4
4
4
4
4
4
6
6
0
066444444421010
   Retained Earnings Total Equity
0
0
0
47
-4,659
-139,950
-120,901
-117,832
0
0
0
-153,580
0
0
0
000-153,580000-117,832-120,901-139,950-4,65947000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
-59,936
0
-50
-82
-69
-18
1
1
-1
0
0-111-18-69-82-500-59,93600000
   Capital Surplus 
0
0
0
4,953
9,658
132,277
138,181
143,112
0
0
0
148,762
0
0
0
000148,762000143,112138,181132,2779,6584,953000
   Treasury Stock000000000000000
   Other Stockholders Equity 
0
0
4,454
166,289
4,817
132,277
138,181
143,112
144,448
145,931
147,476
148,762
164,512
166,276
173,582
173,582166,276164,512148,762147,476145,931144,448143,112138,181132,2774,817166,2894,45400



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-111
Gross Profit-111-111
 
Operating Income (+$)
Gross Profit-111
Operating Expense-33,733
Operating Income-33,844-33,844
 
Operating Expense (+$)
Research Development22,808
Selling General Administrative10,925
Selling And Marketing Expenses0
Operating Expense33,73333,733
 
Net Interest Income (+$)
Interest Income958
Interest Expense-2,919
Other Finance Cost-61
Net Interest Income-1,900
 
Pretax Income (+$)
Operating Income-33,844
Net Interest Income-1,900
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-35,811-31,877
EBIT - interestExpense = -36,763
-35,811
-32,892
Interest Expense2,919
Earnings Before Interest and Taxes (EBIT)-33,844-32,892
Earnings Before Interest and Taxes (EBITDA)-33,733
 
After tax Income (+$)
Income Before Tax-35,811
Tax Provision-0
Net Income From Continuing Ops-35,941-35,811
Net Income-35,811
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses33,844
Total Other Income/Expenses Net-1,9671,900
 

Technical Analysis of Effector
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Effector. The general trend of Effector is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Effector's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Effector Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 8.445 < 8.5375 < 8.625.

The bearish price targets are: .

Tweet this
Effector Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Effector Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Effector Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Effector Therapeutics Inc. The current macd is -2.97160696.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Effector price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Effector. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Effector price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Effector Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartEffector Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Effector Therapeutics Inc. The current adx is 32.94.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Effector shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Effector Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Effector Therapeutics Inc. The current sar is 9.28964944.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Effector Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Effector Therapeutics Inc. The current rsi is 26.67. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Effector Therapeutics Inc Daily Relative Strength Index (RSI) ChartEffector Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Effector Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Effector price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Effector Therapeutics Inc Daily Stochastic Oscillator ChartEffector Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Effector Therapeutics Inc. The current cci is -65.73592263.

Effector Therapeutics Inc Daily Commodity Channel Index (CCI) ChartEffector Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Effector Therapeutics Inc. The current cmo is -56.65287385.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Effector Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartEffector Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Effector Therapeutics Inc. The current willr is -99.80174465.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Effector Therapeutics Inc Daily Williams %R ChartEffector Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Effector Therapeutics Inc.

Effector Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Effector Therapeutics Inc. The current atr is 1.31149236.

Effector Therapeutics Inc Daily Average True Range (ATR) ChartEffector Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Effector Therapeutics Inc. The current obv is -11,866,677.

Effector Therapeutics Inc Daily On-Balance Volume (OBV) ChartEffector Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Effector Therapeutics Inc. The current mfi is 22.48.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Effector Therapeutics Inc Daily Money Flow Index (MFI) ChartEffector Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Effector Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-31WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-01ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Effector Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Effector Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5026.666
Ma 20Greater thanMa 507.576
Ma 50Greater thanMa 10010.440
Ma 100Greater thanMa 20011.033
OpenGreater thanClose1.910
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Effector with someone you think should read this too:
  • Are you bullish or bearish on Effector? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Effector? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Effector Therapeutics Inc

I send you an email if I find something interesting about Effector Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Effector Therapeutics Inc.

Receive notifications about Effector Therapeutics Inc in your mailbox!